CERO
CERO THERAPEUTICS HOLDINGS, INC.Company Information
- Company Name
- CERO THERAPEUTICS HOLDINGS, INC.
- CIK
- CIK0001870404
- Category
- <br>Emerging growth company
- Ticker: Exchange
- CERO: OTC, CEROW: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CERO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2024-12-13
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 8,352,341
Institutional Sentiment
- As of
- 2025-09-30
- Institutional shares owned
- 155,930
- Shares outstanding
- 1,264,884
- Ownership
- 12.33%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 0.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Related Party | - | - | - | - | - | - | - | - | - | - | 2 | - | ||||||
| Series D Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Series E Convertible Preferred Stock | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Series C Convertible Preferred Stock | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Series A Convertible Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Series B Convertible Preferred Stock | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Common Class B | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Assets | ||||||||||||||||||
| Common Class A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | ||||||
| Assets Held In Trust Current | - | - | - | - | - | - | - | - | - | - | 8 | 8 | ||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 1 | 2 | 2 | 3 | - | 3 | 3 | 4 | 5 | 2 | 0 | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | - | - | 0 | 0 | - | - | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 2 | 2 | 3 | 3 | 4 | 6 | 4 | 4 | 4 | 6 | 2 | - | ||||||
| Restricted Cash And Cash Equivalents At Carrying Value | - | - | - | - | 3 | 5 | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | ||||||
| Deferred Costs Current | - | - | - | - | - | - | 0 | - | - | - | - | - | ||||||
| Equity Securities Fv Ni | - | - | - | - | 1 | - | - | - | - | - | - | - | ||||||
| Deferred Costs | - | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | - | ||||||
| Taxes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Assets | 2 | 2 | 4 | 4 | 6 | 8 | 6 | 6 | 7 | 9 | 5 | 8 | ||||||
| Convertible Notes Payable Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Accounts Payable Current | 8 | 8 | 8 | 7 | 6 | 6 | 5 | 7 | 6 | 7 | 2 | 3 | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Accrued Liabilities Current | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | - | ||||||
Long Term Debt And Capital Lease Obligations | ||||||||||||||||||
| Deferred Revenue Noncurrent | - | - | - | - | - | - | - | - | - | - | 9 | - | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 32 | 11 | 9 | 8 | 8 | 8 | 7 | 9 | 9 | 12 | 4 | 5 | ||||||
| Operating Lease Liability Current | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Short Term Bank Loans And Notes Payable | - | - | - | - | - | - | - | 0 | 0 | 0 | 1 | - | ||||||
Redeemable Noncontrolling Interest Equity Redemption Value | ||||||||||||||||||
| Warrants And Rights Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | - | - | - | - | 8 | 8 | ||||||
| Derivative Liabilities Current | 8 | 2 | - | - | - | - | - | - | - | - | - | - | ||||||
| Dividends Payable Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Operating Lease Liability Noncurrent | - | - | - | - | 0 | 0 | 1 | 1 | 1 | 1 | 2 | - | ||||||
| Convertible Debt Noncurrent | - | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
Long Term Liabilities | ||||||||||||||||||
| Liabilities | 32 | 11 | 9 | 8 | 8 | 8 | 8 | 10 | 10 | 13 | 5 | 14 | ||||||
Redeemable Common Stock | ||||||||||||||||||
| Common Stock Value | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Additional Paid In Capital | 66 | 80 | 78 | 73 | 71 | 73 | 67 | 66 | 58 | 54 | 1 | - | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -31 | -9 | -5 | -5 | -2 | -0 | -2 | -4 | -2 | -4 | -42 | -14 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | - | - | - | - | 1 | 1 | ||||||
| Stockholders Equity Note Subscriptions Receivable | -0 | -0 | - | - | -0 | -0 | -1 | -2 | -2 | -3 | - | - | ||||||
| Retained Earnings Accumulated Deficit | -98 | -97 | -91 | -86 | -81 | -76 | -71 | -72 | -67 | -65 | -43 | -14 | ||||||
| Temporary Equity Redemption Price Per Share | - | - | - | - | - | - | - | - | - | - | 11.03 | 10.83 | ||||||
| Liabilities And Stockholders Equity | 2 | 2 | 4 | 4 | 6 | 8 | 6 | 6 | 7 | 9 | 5 | 8 | ||||||
| Series Seed | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series A | - | - | - | - | - | - | - | - | - | - | 25 | - | ||||||
| Common Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | 0.00 | - | ||||||
| Common Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | 45 | - | ||||||
| Common Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Other Liabilities Current | 0 | 0 | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | 10 | - | - | - | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCERO THERAPEUTICS HOLDINGS, INC. (CERO) — SEC Financial Statements & Analysis
CERO THERAPEUTICS HOLDINGS, INC. (CERO) is a biological products, (no diagnostic substances) company, incorporated in DE. CERO THERAPEUTICS HOLDINGS, INC. trades on OTC as: CERO, CEROW. CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, CERO THERAPEUTICS HOLDINGS, INC. carries a market cap of $463.93K, a P/E ratio of -0.01x, a P/B ratio of -0.02x, an enterprise value of $362.61K, and an EV/EBITDA multiple of -0.02x. On profitability, it posts a Return on Equity (ROE) of 569.83% and a Return on Assets (ROA) of -2260.35%. Per share, it reports EPS of $-2.17, diluted EPS of $-2.17, free cash flow per share of $-0.12, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 432.00% year-over-year and EPS growth of -93.84% year-over-year. On the balance sheet, it maintains a current ratio of 0.05x, a quick ratio of 0.03x, working capital of $-30.86M, a debt-to-equity ratio of -1.06x, a debt ratio of 17.06, an interest coverage ratio of -20.07x, free cash flow of $-5.09M (TTM), and net debt of $-101.32K. Figures sourced from SEC EDGAR.
- Market Cap
- $463.93K
- P/E TTM
- -0.01x
- EPS TTM
- $-2.17
- P/B TTM
- -0.02x
- ROE TTM
- 569.83%
- ROA TTM
- -2260.35%
- Debt To Equity
- -1.06x
- Free Cash Flow TTM
- $-5.09M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is CERO THERAPEUTICS HOLDINGS, INC. in?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CERO trade on?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) trades on the OTC.
Where is CERO THERAPEUTICS HOLDINGS, INC. incorporated?
CERO THERAPEUTICS HOLDINGS, INC. is incorporated in DE.
When was CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s most recent SEC filing?
CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CERO's market cap?
CERO THERAPEUTICS HOLDINGS, INC. (CERO) has a market capitalization of $463.93K as of 2026-06-30.
What is CERO's EPS (earnings per share)?
CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s trailing twelve month EPS is $-2.17 as of 2026-06-30.
What is CERO's ROE (return on equity)?
CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s trailing twelve month Return on Equity (ROE) is 569.83% as of 2026-06-30.
What is CERO's ROA (return on assets)?
CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s trailing twelve month Return on Assets (ROA) is -2260.35% as of 2026-06-30.
What is CERO's EV/EBITDA?
CERO THERAPEUTICS HOLDINGS, INC. (CERO)'s trailing twelve month EV/EBITDA is -0.02x as of 2026-06-30.